-
Mashup Score: 6Uveitis Corner - 1 day(s) ago
Long-term results can help guide clinicians’ treatment choices.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 5Clinical Trial Update - 2 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 6Gene Therapy for Wet Age-related Macular Degeneration - 3 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 1Broader VEGF Pathway Inhibition for Wet AMD - 4 day(s) ago
VEGF-C and VEGF-D are innately involved in the neovascular etiology, so treating that component, in addition to traditional anti-VEGF-A treatment, may have the potential for improved VA.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 10Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni - 5 day(s) ago
Dr. Tadayoni was well known internationally for his leadership in retinal surgery and ophthalmic education, and he was a revered mentor and friend.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 0
Atsena Therapeutics has announced that dosing has begun for the second cohort in LIGHTHOUSE, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201, a gene therapy intended to treat X-linked retinoschisis.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 2Subspecialty News - 6 day(s) ago
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 20Polymeric Technologies for Retinal Drug Delivery - 8 day(s) ago
Polymeric technologies have the potential to revolutionize the intravitreal treatment approach for retinal diseases.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 2
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
-
Mashup Score: 5Improving Durability of Drugs in Wet AMD - 10 day(s) ago
Monthly or bimonthly anti-VEGF use poses significant time and cost burden due to the disease’s chronic nature and limited medication half-life. Further potential solutions to address the need for long-acting and more durable therapies include high-concentration anti-VEGF drugs, sustained-release devices, intravitreal reservoirs, suprachoroidal delivery, and gene therapy biofactories.
Source: www.retinalphysician.comCategories: General Medicine News, OphthalmologyTweet
Results of the MERIT Trial for Uveitic Macular Edema: Long-term results can help guide clinicians’ treatment choices. By: Sruthi Arepalli, MD, Douglas A. Jabs, MD, MBA, Nisha Acharya, MD, MS https://t.co/DXo3nnhDYf #uveiticmacularedema #uveitis https://t.co/ptZYFgoPky